SCHEDULE: Morgan Stanley Discloses 6.7% Stake in Taysha Gene Therapies

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed a passive beneficial ownership of 6.7% in Taysha Gene Therapies, Inc. common stock.

Summary

• Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley Capital Services LLC, have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Taysha Gene Therapies, Inc.
• As of June 30, 2025, Morgan Stanley beneficially owns an aggregate of 16,858,644 shares of Taysha Gene Therapies, Inc. common stock, representing 6.7% of the class.
• Morgan Stanley holds shared voting power over 16,651,747 shares and shared dispositive power over 16,858,644 shares.
• Morgan Stanley Capital Services LLC beneficially owns 14,095,143 shares, representing 5.6% of the class, with shared voting and dispositive power over all these shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Taysha Gene Therapies, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by a major financial institution like Morgan Stanley is generally viewed as neutral to slightly positive, indicating institutional interest without implying control or activist intent.

Positives

• A significant stake by a major financial institution like Morgan Stanley may signal confidence in Taysha Gene Therapies, Inc.'s long-term prospects.
• The passive nature of the investment indicates it is held in the ordinary course of business, reducing concerns about potential activist intentions.

Negatives

• No negative information is disclosed in this routine ownership filing.

Risks

• Intentional misstatements or omissions of fact in the filing constitute federal criminal violations.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Taysha Gene Therapies, Inc.'s future performance or strategic direction.

Industry Context

This filing is a routine disclosure of institutional ownership and does not provide specific insights into broader industry trends within the gene therapy or biotechnology sectors, nor does it offer comparative analysis with competitors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a passive stake may provide a degree of confidence or stability, potentially influencing market perception.

Key Dates

Recommendation

This filing primarily serves as a disclosure of a passive ownership stake by a major financial institution. While the presence of a significant institutional investor like Morgan Stanley can be seen as a positive signal, the filing itself does not provide sufficient financial or operational details about Taysha Gene Therapies, Inc. to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further fundamental analysis or company-specific news.

Keywords

Taysha Gene Therapies, Morgan Stanley, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Gene Therapy, Biotechnology